

# RightTrack Report by HEALTH TRACK



## PATIENT INFORMATION

**Name:** Patient Sample  
**DOB:** 01/01/1975  
**Sex at Birth:** M  
**Address:** 123 Resident Street  
City, State, Zip  
**Phone:** 123.456.7890  
**Race:**  
**Ethnicity:**



## SPECIMEN INFORMATION

**Lab Accession Number:** 13044771  
**Menu:** Bronchitis  
**Specimen Type:** Respiratory Tract  
**Date Collected:** 03/15/2026  
**Date Received by Lab:** 03/16/2026  
**Date Reported:** 03/16/2026  
**Cross Reference #:**



## FACILITY INFORMATION

**Facility Name:** Main Street Urgent  
Care  
**Provider Name:** Doctor Test, MD  
**NPI:** 10000000  
**Address:** 123 Main Street  
City, State, Zip  
**Phone:** 555.555.5555

## TEST RESULTS

| ORGANISMS | TARGETS DETECTED | DETECTION STATUS | MICROBIAL LOAD |
|-----------|------------------|------------------|----------------|
|           |                  | Adenovirus       | Detected       |

## TARGETS TESTED

Targets detected are bolded for reference

### BACTERIAL

- Adenovirus
- Chlamydia pneumoniae
- Coronaviruses (229E, NL63, HKU1, OC43)
- Enterovirus D68
- Human metapneumovirus
- Influenza virus A, B
- Parainfluenza virus (PIV types 1, 2, 3, 4)
- Respiratory syncytial virus
- Rhinovirus/Enterovirus
- Bordetella spp (pertussis, parapertussis, bronchispetica)
- Haemophilus influenzae
- Moraxella catarrhalis
- Mycoplasma pneumoniae
- Streptococcus pneumoniae

Analyzed by: Carrie Wilks, PhD *Carrie Wilks*

Date: 11/04/2025 13:16

## Have questions about this report?

Call our Clinical Expert Line at **866-287-3218**.



Real-Time polymerase chain reaction (TaqMan qPCR) was utilized for detection for all tested organisms and resistance genes. Initiation of antimicrobial therapy prior to testing may affect results and can lead to the detection of non-living microorganisms. Detection of microbes must be correlated with current/recent antibiotic usage and patient signs and symptoms. Microbial sensitivity testing is not performed at this lab. Crt to CFU/mL equivalent thresholds were established based on studies using known CFU/mL urine specimens performed at HealthTrackRx in Denton, TX. Testing performed by HealthTrackRx at LabPort (2425 Universal Way Ste 6, Louisville, KY 40219; CLIA# 18D2319534; Lab Director Jessica Moye, PhD, HCLD(ABB)). Data analysis and report release for all tested samples is referred out to HealthTrackRx Indiana, Inc (1500 I35W, Denton, TX 76207; CLIA# 45D2009077) and performed by their appropriately credentialed staff according to CAP and Texas State Requirements. This test was developed, and its performance characteristics determined by HealthTrackRx. This test was developed, and its performance characteristics determined by HealthTrackRx. It has not been cleared or approved by the FDA. However, such approval/clearance is not required, as the laboratory is regulated and qualified under CLIA to perform high-complexity testing. This test is used for clinical purposes and should not be regarded as investigational or for research.

\*Approximate copies of target nucleic acid per &micro;L (Low: <2,500 copies/&micro;L; Moderate: 2,500-50,000 copies/&micro;L; High: >50,000 copies/&micro;L)

HealthTrackRx owns and operates the following laboratories: HEALTHTRACKRX INDIANA, INC. (NPI: 1104631415, CLIA: 18D2319534, Lab Director: Carrie Wilks, PhD, HCLD(ABB)), (NPI: 1689639544, CLIA: 45D2009077, Lab Director: Rhiannon Gonzalez, PhD, HCLD(ABB)), (NPI: 1326743535, CLIA: 15D2267792, Lab Director: Jessica Moye, PhD, HCLD(ABB)), HEALTHTRACKRX OF LOUISIANA, LLC (NPI: 1265206155, CLIA: 15D2294984, Lab Director: Carrie Wilks, PhD, HCLD(ABB)), HEALTHTRACKRX OF MARYLAND, LLC (NPI: 1588498091, CLIA: 15D2311036, Lab Director: Carrie Wilks, PhD, HCLD(ABB)), HEALTHTRACKRX OF CALIFORNIA, LLC (NPI: 1790470763, CLIA: 05D2287227, Lab Director: Joshua Brown, PhD, HCLD(ABB)).